Last reviewed · How we verify
6-mercaptopurine, Methotrexate, Vincristine, Dexamethasone
6-mercaptopurine, Methotrexate, Vincristine, Dexamethasone is a Small molecule drug developed by Sun Yat-sen University. It is currently FDA-approved. Also known as: For SR and IR patients (Group two).
At a glance
| Generic name | 6-mercaptopurine, Methotrexate, Vincristine, Dexamethasone |
|---|---|
| Also known as | For SR and IR patients (Group two) |
| Sponsor | Sun Yat-sen University |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia (PHASE2)
- A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia (PHASE3)
- Pediatric-Inspired Regimen Combined With Venetoclax and Immunotherapy for Adult Ph-Negative Acute Lymphoblastic Leukemia (NA)
- Capizzi Escalating Methotrexate Versus High Dose Methotrexate in Children With Newly Diagnosed T-cell Lymphoblastic Lymphoma (T-LBL) (PHASE3)
- LBL-2016 for Children or Adolescents in China (PHASE3)
- Asparaginase Erwinia Chrysanthemi With Chemotherapy for the Treatment of High-Risk Adults With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma (PHASE2)
- A Phase 2 Study of Ruxolitinib With Chemotherapy in Children With Acute Lymphoblastic Leukemia (PHASE2)
- Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- 6-mercaptopurine, Methotrexate, Vincristine, Dexamethasone CI brief — competitive landscape report
- 6-mercaptopurine, Methotrexate, Vincristine, Dexamethasone updates RSS · CI watch RSS
- Sun Yat-sen University portfolio CI
Frequently asked questions about 6-mercaptopurine, Methotrexate, Vincristine, Dexamethasone
What is 6-mercaptopurine, Methotrexate, Vincristine, Dexamethasone?
6-mercaptopurine, Methotrexate, Vincristine, Dexamethasone is a Small molecule drug developed by Sun Yat-sen University.
Who makes 6-mercaptopurine, Methotrexate, Vincristine, Dexamethasone?
6-mercaptopurine, Methotrexate, Vincristine, Dexamethasone is developed and marketed by Sun Yat-sen University (see full Sun Yat-sen University pipeline at /company/sun-yat-sen-university).
Is 6-mercaptopurine, Methotrexate, Vincristine, Dexamethasone also known as anything else?
6-mercaptopurine, Methotrexate, Vincristine, Dexamethasone is also known as For SR and IR patients (Group two).
What development phase is 6-mercaptopurine, Methotrexate, Vincristine, Dexamethasone in?
6-mercaptopurine, Methotrexate, Vincristine, Dexamethasone is FDA-approved (marketed).
Related
- Manufacturer: Sun Yat-sen University — full pipeline
- Also known as: For SR and IR patients (Group two)
- Compare: 6-mercaptopurine, Methotrexate, Vincristine, Dexamethasone vs similar drugs
- Pricing: 6-mercaptopurine, Methotrexate, Vincristine, Dexamethasone cost, discount & access